Long-term gene expression in dividing and nondividing cells using SV40-derived vectors
- PMID: 17172671
- DOI: 10.1385/MB:34:2:257
Long-term gene expression in dividing and nondividing cells using SV40-derived vectors
Abstract
Among the goals of gene therapy is long-term expression of delivered transgenes. Recombinant Tagdeleted SV40 vectors (rSV40s) are especially well suited for this purpose. rSV40s deliver transgene expression that endures for extended periods of time in tissue culture and in vivo, in both dividing and nondividing cells. These vectors are particularly effective in transducing some cell types that have been almost unapproachable using other gene delivery systems, such as quiescent hematopoietic progenitor cells and their differentiated derivatives. Other cellular targets include neurons, brain microglia, hepatocytes, dendritic cells, vascular endothelium, and others. Because rSV40s do not elicit neutralizing antibodies they are useful for in vivo gene delivery in settings where more than one administration may be desirable. The key characteristics of these vectors include their high production titers and therefore suitability for large cell pools, effectiveness in delivering intracellular proteins, and untranslated RNAs, maintenance of transgene expression at constant levels for extended times, suitability for constitutive or conditional promoters and for combinatorial gene delivery and ability to integrate into genomes of both dividing and nondividing cells.
Similar articles
-
Durability of transgene expression and vector integration: recombinant SV40-derived gene therapy vectors.Mol Ther. 2002 Aug;6(2):227-37. doi: 10.1006/mthe.2002.0657. Mol Ther. 2002. PMID: 12161189
-
Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.Gene Ther. 2000 May;7(10):886-95. doi: 10.1038/sj.gt.3301159. Gene Ther. 2000. PMID: 10845727
-
Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe.Gene Ther. 2011 Jul;18(7):682-91. doi: 10.1038/gt.2011.13. Epub 2011 Mar 3. Gene Ther. 2011. PMID: 21368898
-
Gene therapy using SV40-derived vectors: what does the future hold?J Cell Physiol. 1999 Dec;181(3):375-84. doi: 10.1002/(SICI)1097-4652(199912)181:3<375::AID-JCP1>3.0.CO;2-8. J Cell Physiol. 1999. PMID: 10528223 Review.
-
SV40-based gene therapy vectors: turning an adversary into a friend.Curr Opin Mol Ther. 2000 Oct;2(5):570-8. Curr Opin Mol Ther. 2000. PMID: 11249759 Review.
Cited by
-
Pseudovirions as vehicles for the delivery of siRNA.Pharm Res. 2010 Mar;27(3):400-20. doi: 10.1007/s11095-009-0012-2. Epub 2009 Dec 9. Pharm Res. 2010. PMID: 19998056 Free PMC article.
-
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.Biologics. 2009;3:245-56. Epub 2009 Jul 13. Biologics. 2009. PMID: 19707413 Free PMC article.
-
Current approaches to enhance CNS delivery of drugs across the brain barriers.Int J Nanomedicine. 2014 May 10;9:2241-57. doi: 10.2147/IJN.S61288. eCollection 2014. Int J Nanomedicine. 2014. PMID: 24872687 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical